These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 32308206)

  • 41. The role of icatibant-the B2 bradykinin receptor antagonist-in life-threatening laryngeal angioedema in the ED.
    Bartal C; Zeldetz V; Stavi V; Barski L
    Am J Emerg Med; 2015 Mar; 33(3):479.e1-3. PubMed ID: 25241359
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Hereditary and acquired angioedema: clinical characteristics in 8 patients and review of the literature].
    Fonseca Aizpuru EM; Rodríguez Avila EE; Arias Miranda I; Nuño Mateo FJ
    Rev Clin Esp; 2009; 209(7):332-6. PubMed ID: 19709536
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hereditary angioedema: epidemiology, management, and role of icatibant.
    Ghazi A; Grant JA
    Biologics; 2013; 7():103-13. PubMed ID: 23662043
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Frequent life-threatening laryngeal attacks in two Croatian families with hereditary angioedema due to C1 inhibitor deficiency harbouring a novel frameshift mutation in SERPING1.
    Karadža-Lapić L; Korošec P; Šilar M; Košnik M; Cikojević D; Lozić B; Rijavec M
    Ann Med; 2016 Nov; 48(7):485-491. PubMed ID: 27187751
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The safety of treatments for angioedema with hereditary C1 inhibitor deficiency.
    Zanichelli A; Wu MA; Andreoli A; Mansi M; Cicardi M
    Expert Opin Drug Saf; 2015; 14(11):1725-36. PubMed ID: 26429506
    [TBL] [Abstract][Full Text] [Related]  

  • 46. An ABC of the Warning Signs of Hereditary Angioedema.
    Grumach AS; Ferraroni N; Olivares MM; López-Serrano MC; Bygum A
    Int Arch Allergy Immunol; 2017; 174(1):1-6. PubMed ID: 28950264
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency.
    Zanichelli A; Mansi M; Azin GM; Wu MA; Periti G; Casazza G; Vacchini R; Suffritti C; Cicardi M
    Allergy; 2015 Dec; 70(12):1553-8. PubMed ID: 26304015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term prophylaxis in patients with angioedema due to C1-inhibitor deficiency undergoing dental procedures: An observational study.
    Zanichelli A; Ghezzi M; Santicchia I; Vacchini R; Cicardi M; Sparaco A; Donati G; Ranìa V; Busa A
    PLoS One; 2020; 15(3):e0230128. PubMed ID: 32163480
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy, pharmacokinetics, and safety of icatibant for the treatment of Japanese patients with an acute attack of hereditary angioedema: A phase 3 open-label study.
    Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
    Allergol Int; 2020 Apr; 69(2):268-273. PubMed ID: 31672405
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Open-label, multicenter study of self-administered icatibant for attacks of hereditary angioedema.
    Aberer W; Maurer M; Reshef A; Longhurst H; Kivity S; Bygum A; Caballero T; Bloom B; Nair N; Malbrán A
    Allergy; 2014 Mar; 69(3):305-14. PubMed ID: 24438203
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of COVID-19 on hereditary angioedema activity and quality of life.
    Can Bostan O; Tuncay G; Damadoglu E; Karakaya G; Kalyoncu AF
    Allergy Asthma Proc; 2021 Sep; 42(5):403-408. PubMed ID: 34474710
    [No Abstract]   [Full Text] [Related]  

  • 52. Investigational drugs in phase I and phase II clinical trials for hereditary angioedema.
    Farkas H; Debreczeni ML; Kőhalmi KV
    Expert Opin Investig Drugs; 2018 Jan; 27(1):87-103. PubMed ID: 29226721
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Update on the acute treatment of hereditary angioedema.
    Riedl MA
    Allergy Asthma Proc; 2011; 32(1):11-6. PubMed ID: 21262093
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical Characteristics and Management of Angioedema Attacks in Polish Adult Patients with Hereditary Angioedema Due to C1-Inhibitor Deficiency.
    Piotrowicz-Wójcik K; Bulanda M; Juchacz A; Jamróz-Brzeska J; Gocki J; Kuziemski K; Pawłowicz R; Porebski G
    J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884311
    [TBL] [Abstract][Full Text] [Related]  

  • 55. When is prophylaxis for hereditary angioedema necessary?
    Craig T; Riedl M; Dykewicz MS; Gower RG; Baker J; Edelman FJ; Hurewitz D; Jacobs J; Kalfus I
    Ann Allergy Asthma Immunol; 2009 May; 102(5):366-72. PubMed ID: 19492656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Icatibant for the treatment of hereditary angioedema.
    Cole SW; Lundquist LM
    Ann Pharmacother; 2013 Jan; 47(1):49-55. PubMed ID: 23249729
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diagnosis and treatment of hereditary angioedema.
    Canonica GW; Rossi O
    Panminerva Med; 2012 Sep; 54(3):241-53. PubMed ID: 22801442
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Progress with management of hereditary angioedema].
    Johnston DT; Lode H
    MMW Fortschr Med; 2013 Mar; 155 Suppl 1():1-5. PubMed ID: 23678665
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Icatibant. Attacks of hereditary angioedema: continue to use C1 esterase inhibitor.
    Prescrire Int; 2010 Nov; 19(110):245-7. PubMed ID: 21284353
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [EFFICACY, PHARMACOKINETICS, AND SAFETY OF ICATIBANT FOR THE TREATMENT OF JAPANESE PATIENTS WITH AN ACUTE ATTACK OF HEREDITARY ANGIOEDEMA: A PHASE 3 OPEN-LABEL STUDY].
    Hide M; Fukunaga A; Maehara J; Eto K; Hao J; Vardi M; Nomoto Y
    Arerugi; 2018; 67(2):139-147. PubMed ID: 29553114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.